Sensei Biotherapeutics Statistics
Share Statistics
Sensei Biotherapeutics has 25.15M shares outstanding. The number of shares has increased by 0.32% in one year.
| Shares Outstanding | 25.15M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 16.54M |
| Failed to Deliver (FTD) Shares | 3.95K |
| FTD / Avg. Volume | 0.82% |
Short Selling Information
The latest short interest is 194.69K, so 0.77% of the outstanding shares have been sold short.
| Short Interest | 194.69K |
| Short % of Shares Out | 0.77% |
| Short % of Float | 1.18% |
| Short Ratio (days to cover) | 0.29 |
Valuation Ratios
The PE ratio is -0.57 and the forward PE ratio is -0.48.
| PE Ratio | -0.57 |
| Forward PE | -0.48 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.3 |
| P/FCF Ratio | -0.6 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Sensei Biotherapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.92, with a Debt / Equity ratio of 0.
| Current Ratio | 11.92 |
| Quick Ratio | 11.92 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -257.39 |
Financial Efficiency
Return on equity (ROE) is -0.53% and return on capital (ROIC) is -52.13%.
| Return on Equity (ROE) | -0.53% |
| Return on Assets (ROA) | -0.46% |
| Return on Capital (ROIC) | -52.13% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.22M |
| Employee Count | 28 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -32.48% in the last 52 weeks. The beta is 0.06, so Sensei Biotherapeutics 's price volatility has been higher than the market average.
| Beta | 0.06 |
| 52-Week Price Change | -32.48% |
| 50-Day Moving Average | 0.5 |
| 200-Day Moving Average | 0.73 |
| Relative Strength Index (RSI) | 54.26 |
| Average Volume (20 Days) | 482.46K |
Income Statement
| Revenue | n/a |
| Gross Profit | -571.00K |
| Operating Income | -37.06M |
| Net Income | -34.10M |
| EBITDA | -33.39M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.22 |
Balance Sheet
The company has 13.01M in cash and 6.21M in debt, giving a net cash position of 6.80M.
| Cash & Cash Equivalents | 13.01M |
| Total Debt | 6.21M |
| Net Cash | 6.80M |
| Retained Earnings | -231.90M |
| Total Assets | 53.25M |
| Working Capital | 42.66M |
Cash Flow
In the last 12 months, operating cash flow was -32.02M and capital expenditures -180.00K, giving a free cash flow of -32.20M.
| Operating Cash Flow | -32.02M |
| Capital Expenditures | -180.00K |
| Free Cash Flow | -32.20M |
| FCF Per Share | -1.15 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SNSE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -234.62% |
| FCF Yield | -244.34% |
Analyst Forecast
The average price target for SNSE is $4, which is 669.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $4 |
| Price Target Difference | 669.2% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -6.61 |
| Piotroski F-Score | 3 |